<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We produced an antiserum by immunizing rabbits with purified human megakaryocyte colony stimulating factor (Meg-CSF) </plain></SENT>
<SENT sid="1" pm="."><plain>With the use of an anti-Meg-CSF IgG fraction (AM-IgG), we detected immunoreactive Meg-CSF both in human <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> serum (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AAS</z:e>) and <z:mpath ids='MPATH_458'>normal</z:mpath> serum </plain></SENT>
<SENT sid="2" pm="."><plain>Based on our immunological and biological analyses, Meg-CSF appeared to be antigenically as well as functionally distinct from human urinary erythropoietin (EPO) and thrombopoietic stimulating factor </plain></SENT>
<SENT sid="3" pm="."><plain>The AM-IgG fraction was able to suppress the ability of both <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> serum and purified Meg-CSF to promote megakaryocyte colony formation </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, the supernatant formed after immune precipitation of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AAS</z:e> with AM-IgG no longer possessed Meg-CSF-like activity </plain></SENT>
<SENT sid="5" pm="."><plain>The AM-IgG did not suppress the ability of EPO, phytohemagglutinin-stimulated leukocyte conditioned medium (PHA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCM</z:e>), or PHA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCM</z:e> + EPO to promote erythroid, granulocyte-macrophage, or mixed colony formation, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The use of this antibody has further defined the dependency of human megakaryocytopoiesis on Meg-CSF </plain></SENT>
</text></document>